AREDS2 Under Scrutiny: Advocating Unified Regulations

Abstract

Background Age-related macular degeneration (AMD) is one of the leading causes of blindness in older adults. Dietary supplements based on the AREDS2 formulation are considered an evidence-based intervention to slow disease progression in intermediate AMD.

Objective This study aimed to systematically compare the composition of over-the-counter dietary supplements marketed for AMD support with the original AREDS2 formula and to quantify any deviations.

Methods As part of a market analysis, products available in Germany claiming a supportive effect in AMD were identified. The ingredients and dosages declared on the packaging were compared with the reference values used in the AREDS2 study.

Results The majority of analysed supplements exhibited substantial deviations from the AREDS2 formulation. On average, the concentrations of vitamin C were 52.3% lower, vitamin E 61.2% lower, and zinc 40.1% lower than the recommended amounts. Only a minority of products matched the reference formulation in both composition and dosage.

Conclusion There are significant discrepancies in the composition of commercially available AREDS2-based supplements. The implementation of standardised labelling requirements and regulatory guidelines appears necessary to enhance comparability and support evidence-based use in clinical practice.

Keywords

AREDS2 - AMD - prevention - nutritional supplements

Publication History

Received: 27 January 2025

Accepted: 13 May 2025

Article published online:
24 July 2025

• References/Literatur

• 1 Thomas CJ, Mirza RG, Gill MK. Age-Related Macular Degeneration. Med Clin North Am 2021; 105: 473-491
• 2 Congdon N, OʼColmain B, Klaver CC. et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004; 122: 477-485
• 3 Vyawahare H, Shinde P. Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment. Cureus 2022; 14: e29583
• 4 Guymer RH, Campbell TG. Age-related macular degeneration. Lancet 2023; 401: 1459-1472
• 5 Flores R, Carneiro Â, Vieira M. et al. Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives. Ophthalmologica 2021; 244: 495-511
• 6 Heier JS, Lad EM, Holz FG. et al. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials. Lancet 2023; 402: 1434-1448
• 7 Singh N, Srinivasan S, Muralidharan V. et al. Prevention of Age-Related Macular Degeneration. Asia Pac J Ophthalmol (Phila) 2017; 6: 520-526
• 8 Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study (AREDS): design implications. AREDS report No. 1. Controlled Clinical Trials 1999; 20: 573-600
• 9 Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study system for classifying age-related macular degeneration from stereoscopic color fundus photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol 2001; 132: 668-681
• 10 Albanes D, Heinonen O, Huttunen J. et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995; 62 (6 Suppl): 1427S-1430S
• 11 Omenn GS, Goodman GE, Thornquist MD. et al. Risk Factors for Lung Cancer and for Intervention Effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996; 88: 1550-1559
• 12 Age-Related Eye Disease Study 2 (AREDS2) Research Group. Chew EY, Clemons TE, Sangiovanni JP. et al. Secondary Analyses of the Effects of Lutein/Zeaxanthin on Age-Related Macular Degeneration Progression: AREDS2 Report No. 3. JAMA Ophthalmol 2014; 132: 142
• 13 Alghamdi A, Keegan D, Connell P. et al. Adherence of patients with age-related macular degeneration to AREDS2-recommended nutritional supplements. Ir J Med Sci 2023; 192: 3163-3167
• 14 Chang CW, Chu G, Hinz BJ. et al. Current use of dietary supplementation in patients with age-related macular degeneration. Can J Ophthalmol 2003; 38: 27-32
• 15 Niki E, Traber MG. A history of vitamin E. Ann Nutr Metab 2012; 61: 207-212
• 16 Paudel N, Brady L, Stratieva P. et al. Economic Burden of Late-Stage Age-Related Macular Degeneration in Bulgaria, Germany, and the US. JAMA Ophthalmol 2024; 142: 1123
• 17 Keenan TDL, Agrón E, Keane PA. et al. Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration. Ophthalmology 2025; 132: 14-29